230 related articles for article (PubMed ID: 12712417)
1. Immobilization of fine particles on lactose carrier by precision coating and its effect on the performance of dry powder formulations.
Chan LW; Lim LT; Heng PW
J Pharm Sci; 2003 May; 92(5):975-84. PubMed ID: 12712417
[TBL] [Abstract][Full Text] [Related]
2. Effects of surface processing of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
Iida K; Inagaki Y; Todo H; Okamoto H; Danjo K; Luenberger H
Chem Pharm Bull (Tokyo); 2004 Aug; 52(8):938-42. PubMed ID: 15304985
[TBL] [Abstract][Full Text] [Related]
3. Effect of surface layering time of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenberger H
Chem Pharm Bull (Tokyo); 2004 Mar; 52(3):350-3. PubMed ID: 14993760
[TBL] [Abstract][Full Text] [Related]
4. Preparation of dry powder inhalation with lactose carrier particles surface-coated using a Wurster fluidized bed.
Iida K; Todo H; Okamoto H; Danjo K; Leuenberger H
Chem Pharm Bull (Tokyo); 2005 Apr; 53(4):431-4. PubMed ID: 15802846
[TBL] [Abstract][Full Text] [Related]
5. Characterizing the Surface Roughness Length Scales of Lactose Carrier Particles in Dry Powder Inhalers.
Tan BMJ; Chan LW; Heng PWS
Mol Pharm; 2018 Apr; 15(4):1635-1642. PubMed ID: 29490144
[TBL] [Abstract][Full Text] [Related]
6. Quantification of the surface morphologies of lactose carriers and their effect on the in vitro deposition of salbutamol sulphate.
Heng PW; Chan LW; Lim LT
Chem Pharm Bull (Tokyo); 2000 Mar; 48(3):393-8. PubMed ID: 10726864
[TBL] [Abstract][Full Text] [Related]
7. Effect of surface covering of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenbergerb H
Chem Pharm Bull (Tokyo); 2003 Dec; 51(12):1455-7. PubMed ID: 14646332
[TBL] [Abstract][Full Text] [Related]
8. Surface Modification of lactose carrier particles using a fluid bed coater to improve fine particle fraction for dry powder inhalers.
Gong QQ; Tay JYS; Veronica N; Xu J; Heng PWS; Zhang YP; Liew CV
Pharm Dev Technol; 2023 Feb; 28(2):164-175. PubMed ID: 36683577
[TBL] [Abstract][Full Text] [Related]
9. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone.
Kaialy W; Ticehurst MD; Murphy J; Nokhodchi A
J Pharm Sci; 2011 Jul; 100(7):2665-84. PubMed ID: 21268026
[TBL] [Abstract][Full Text] [Related]
10. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
11. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 1. Albuterol sulfate and disodium cromoglycate.
Xu Z; Mansour HM; Mulder T; McLean R; Langridge J; Hickey AJ
J Pharm Sci; 2010 Aug; 99(8):3398-414. PubMed ID: 20198688
[TBL] [Abstract][Full Text] [Related]
12. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers.
Schiavone H; Palakodaty S; Clark A; York P; Tzannis ST
Int J Pharm; 2004 Aug; 281(1-2):55-66. PubMed ID: 15288343
[TBL] [Abstract][Full Text] [Related]
14. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
Kaialy W; Ticehurst M; Nokhodchi A
Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
[TBL] [Abstract][Full Text] [Related]
15. Influence of storage humidity on the in vitro inhalation properties of salbutamol sulfate dry powder with surface covered lactose carrier.
Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenberger H
Chem Pharm Bull (Tokyo); 2004 Apr; 52(4):444-6. PubMed ID: 15056961
[TBL] [Abstract][Full Text] [Related]
16. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
17. Dry powder inhaler performance of spray dried mannitol with tailored surface morphologies as carrier and salbutamol sulphate.
Mönckedieck M; Kamplade J; Fakner P; Urbanetz NA; Walzel P; Steckel H; Scherließ R
Int J Pharm; 2017 May; 524(1-2):351-363. PubMed ID: 28347847
[TBL] [Abstract][Full Text] [Related]
18. Influence of carrier surface fines on dry powder inhalation formulations.
Boshhiha AM; Urbanetz NA
Drug Dev Ind Pharm; 2009 Aug; 35(8):904-16. PubMed ID: 19466888
[TBL] [Abstract][Full Text] [Related]
19. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
[TBL] [Abstract][Full Text] [Related]
20. The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate.
Larhrib H; Zeng XM; Martin GP; Marriott C; Pritchard J
Int J Pharm; 1999 Nov; 191(1):1-14. PubMed ID: 10556735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
